In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing firstname.lastname@example.org with the subject line SUBSCRIBE LRG SCIENCE.
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]
Are you interested in optimizing your treatment? In 'Optimizing GIST Treatment', this world-renown GIST expert from Europe will share his wealth of experience and insight about how he has helped patients live longer, and [...]
New Drug Approved for Patients with Rare Gene Fusion By Sara Rothschild, MPH, Vice President, Program Services & Jerry Call, Data Analyst The Food and Drug Administration granted accelerated approval on November 26th to [...]
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
On February 1, 2016, there was a commercial launch of the generic version of imatinib mesylate (Gleevec) which is approved for CML patients by the FDA. As the first to file for generic marketing [...]
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time in the United States through Sun Pharmaceuticals. In response to this transition, the LRG provided an educational Webinar to the CML and GIST communities on March 18th entitled “Generic Imatinib: Gaining Perspective.”